AdipoGen Life Sciences


CHF 40.00
In stock
AG-CR1-3567-M0011 mgCHF 40.00
AG-CR1-3567-M0055 mgCHF 115.00
More Information
Product Details
Synonyms Demecolcine; BRN 2822892
Product Type Chemical


MW 371.4
Merck Index 14: 2887
CAS 477-30-5
Source/Host Chemicals Semisynthetic from colchicine (Prod. No. AG-CN2-0048).
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white/light yellow powder.
Solubility Soluble in ethanol, DMSO or chloroform.
Identity Determined by 1H-NMR.
Smiles O=C1C(OC)=CC=C(C([C@@H](NC)CC2)=C1)C3=C2C=C(OC)C(OC)=C3OC
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Anti-cancer compound [2, 6, 7, 10, 11, 14].
  • Cell synchronization agent. Used as a drug in chemotherapy by synchronizing tumor cells at metaphase, the radiosensitive stage of the cell cycle [11, 12, 14].
  • Microtubule assembly inhibitor. Depolymerizes microtubules and limits microtubule formation (inactivates spindle fibre formation) [1, 4, 5, 14].
  • Inhibits mitosis during cell division at metaphase by inhibiting spindle formation [2, 5, 7, 8, 14].
  • Low concentrations affect microtubule dynamics and cell migration, while high concentrations promote microtubule detachment from microtubule organizing center [14].
  • Apoptosis inducer [9, 13].
  • Thrombopoietic agent [3].
Product References
  1. Effect of colcemid on fibroblast motility: M.H. Gail & C.W. Boone; Exp. Cell Res. 65, 221 (1971)
  2. Mitosis in human leukemic leukocytes during colcemid inhibition and recovery: M. McGill & B. R. Brinkley; Cancer Res. 32, 746 (1972)
  3. The effects of colcemid on hematopoiesis in the mouse: P.A. Bunn Jr., et al.; J. Clin. Invest. 58, 1280 (1976)
  4. Colcemid and colchicine binding to tubulin. Similarity and dissimilarity: A.C. Banerjee & B. Bhattacharyya; FEBS Lett. 99, 333 (1979)
  5. Comparison of mitostatic effect, cell uptake and tubulin-binding activity on colchicine and colcemid: A.S. Serpinskaya, et al.; Biochim. Biophys. Acta 673, 86 (1981)
  6. Action of demecolcine (colcemid) in the murine sarcoma 180 tumor: T. Nomura & J.E. Plager; Cancer Treat. Rep. 65, 283 (1981)
  7. Colcemid effects on B16 melanoma cell progression and aberrant mitotic division: B.K. Bhuyan, et al.; J. Cell Physiol. 132, 237 (1987)
  8. Colcemid and the mitotic cycle: C.L. Rieder & R.E. Palazzo; J. Cell. Sci. 102, 387 (1992)
  9. Induction of apoptosis by the anti-tubulin drug colcemid: relationship of mitotic checkpoint control to the induction of apoptosis in HeLa S3 cells: S.W. Sherwood, et al.; Exp. Cell. Res. 215, 373 (1994)
  10. Effects of colcemid concentration on chromosome aberration analysis in human lymphocytes: R. Kanda, et al.; J. Radiat. Res. (Tokyo) 35, 41 (1994)
  11. Cell cycle arrest by Colcemid differs in human normal and tumor cells: M.N. Jha, et al.; Cancer Res. 54, 5011 (1994)
  12. Dissociation of nuclear and cytoplasmic cell cycle progression by drugs employed in cell synchronization: L. Urbani, et al.; Exp. Cell. Res. 219, 159 (1995)
  13. Expression of apoptosis and cell cycle related genes in proliferating and colcemid arrested cells of divergent lineage: B.W. Gallaher, et al.; Cell. Mol. Biol. 46, 79 (2000)
  14. Inhibition of Cell Migration and Cell Division Correlates with Distinct Effects of Microtubule Inhibiting Drugs: H. Yang, et al.; J. Biol. Chem. 285, 32242 (2010)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.